To register for the Free SmallCapReview Newsletter visit http://www.smallcapreview.com.htm/
ICF Incorporated, LLC, a subsidiary of ICF International (Nasdaq: ICFI) Closed at $23.91. Today announced that it was awarded a new subcontract to provide services to the Department of Health and Human Services (HHS) Administration for Children and Families’ (ACF) Children’s Bureau to conduct a cross-site evaluation of its Training and Technical Assistance (T/TA) Network. The agreement, which consists of five base and two option years, started in September 2008 and has a total value of $2.2 million.
What They Do: ICF International partners with government and commercial clients to deliver consulting services and technology solutions in the energy, climate change, environment, transportation, social programs, health, defense, and emergency management markets.
Spectrum Pharmaceuticals (Nasdaq: SPPI) Closed at $1.49. Today announced the closing of the transaction whereby Spectrum Pharmaceuticals acquired 100% control of RIT Oncology, LLC, to commercialize ZEVALIN ([90Y]-ibritumomab tiuxetan) in the United States. In connection with the closing, Spectrum Pharmaceuticals will pay its former partner a total of $16.5 million, which is subject to further adjustments based on outstanding liabilities and obligations. Additionally, there will be no further payments or milestones to the former partner. Spectrum Pharmaceuticals now has 100% ownership of RIT Oncology, LLC, and will be responsible for all activities relating to ZEVALIN. Spectrum Pharmaceuticals will now book 100% of ZEVALIN revenues.
ZEVALIN is currently approved for the treatment of patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL), including patients who have rituximab-refractory follicular NHL. ZEVALIN is under review by the FDA for use as a first line consolidation therapy for patients with NHL. The FDA recently established July 2, 2009 as a target date for a decision regarding the ZEVALIN sBLA.
What They Do: Spectrum is a biopharmaceutical company that acquires, develops and commercializes a diversified portfolio of drug products, with a focus mainly on oncology and urology. Spectrum's strategy is comprised of acquiring and developing a broad and diverse pipeline of late-stage clinical and commercial products; establishing a commercial organization for our approved drugs; continuing to build a team with people who have demonstrated skills, passion, commitment and have a track record of success in developing drugs and commercialization in our areas of focus; and, leveraging the expertise of partners around the world to assist us in the execution of our strategy.
XenoPort (Nasdaq: XNPT) Closed at $19.99. Today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the new drug application (NDA) filed by GlaxoSmithKline (GSK) for Solzira (gabapentin enacarbil) Extended Release Tablets in the United States as a potential treatment for moderate-to-severe primary Restless Legs Syndrome (RLS). In accordance with XenoPort’s collaboration agreements with GSK and Astellas Pharma Inc., the FDA’s acceptance of the NDA triggers milestone payments to XenoPort of $23 million in the aggregate.
What They Do: XenoPort, Inc. is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates that utilize the body’s natural nutrient transport mechanisms to improve the therapeutic benefits of existing drugs.
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com has been a leading site for news on small-cap stocks since 1999. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select small-cap stocks, to register visit http://www.smallcapreview.com/.
